Clinical Trial Update: Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration [Phase 2]

View source ↗

Summary

Phase 2 trial suggests that reducing the usual intravenous lipid administration in extremely preterm infants may lower the risk of bilirubin neurotoxicity and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bilirubin Encephalopathy

Drugs mentioned

• Intravenous lipid emulsion (intravenous lipid emulsion)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Bilirubin Encephalopathy | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-28